Because somatic HER2‐Neu mutations activate the HER2‐Neu oncogene without its amplification, Trastuzumab and other commonly used HER2‐Neu directed agents are usually ineffective in HER2‐Neu‐mutated BC. The gene discussed is ERBB2; the disease is breast cancer.